跳至主要内容
临床试验/NCT03321136
NCT03321136已完成早期 1 期

Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2017年11月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
16
试验地点
1
主要终点
Altered states of consciousness

研究概览

简要总结

Serotonin receptors, especially the 5HT2A receptor, are thought to be involved in the effects of various recreationally used psychedelic substances such as LSD. LSD potently stimulates the 5-HT2A receptor but also 5-HT2B/C, 5-HT1 and dopaminergic receptors. LSD induces acute transient alterations in waking consciousness including visual perceptual alterations, audio-visual synesthesia, derealization and depersonalization. LSD has therefore been used as experimental tool ("psychotomimetic") in modern psychiatric research to study psychotic-like states and model psychosis in healthy subjects [1-5]. However, the dose-effects of 5-HT2A receptor stimulation by LSD has not yet been studied. Additionally, there is still very limited data to what extent the 5HT2A receptor contributes to LSD's effects and its role in the mediation of the full response to LSD at a high dose is unclear. A recent experimental human study showed the 5-HT2A receptor antagonist ketanserin fully blocked the subjective effects of a moderate dose of 100 µg of LSD [6]. But, whether the effects of a high 200 µg oral dose of LSD can be blocked by the selective pharmacological 5-HT2A antagonist ketanserin remains to be tested to confirm the critical role of the 5-HT2A receptor in more pronounced alterations of consciousness and perception. The present study therefore explores the role the 5-HT2A receptor in LSD-induced altered states of consciousness using escalating doses of LSD and the 5-HT2A receptor blocker ketanserin administered before a high dose of LSD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 25 and 65 years.
  • Understanding of the German language.
  • Understanding the procedures and the risks associated with the study.
  • Participants must be willing to adhere to the protocol and sign the consent form.
  • Participants must be willing to refrain from taking illicit psychoactive substances during the study.
  • Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drink after midnight of the evening before the study session, as well as during the study day.
  • Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration.
  • Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session.
  • Women of childbearing potential must be willing to use double-barrier birth control
  • Body mass index 18-29 kg/m2.

排除标准

  • Chronic or acute medical condition
  • Current or previous major psychiatric disorder
  • Psychotic disorder in first-degree relatives
  • Illicit substance use (with the exception of cannabis) more than 10 times or any time within the previous two months.
  • Pregnant or nursing women.
  • Participation in another clinical trial (currently or within the last 30 days)
  • Use of medications that may interfere with the effects of the study medications (any psychiatric medications)
  • Tobacco smoking (>10 cigarettes/day)
  • Consumption of alcoholic drinks (>10/week)

研究组 & 干预措施

Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: LSD (Drug)

Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: Placebo (Drug)

LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: LSD (Drug)

LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: Placebo (Drug)

LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: LSD (Drug)

LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: Placebo (Drug)

LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: LSD (Drug)

LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: Placebo (Drug)

LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: LSD (Drug)

LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: Placebo (Drug)

LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: LSD (Drug)

LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200

Placebo Comparator

Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase

干预措施: Placebo (Drug)

结局指标

主要结局

Altered states of consciousness

时间窗: 18 months

total 5D-ASC score (5-Dimensional Altered States of Consciousness Rating Scale)

次要结局

  • Subjective effects(18 months)
  • Psychotomimetic effects(18 months)
  • Mystical-type experiences(18 months)
  • Autonomic effects(18 months)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验